The prevalence of type 2 diabetes, along with related conditions, such as metabolic syndrome and obesity, has increased globally in the past two decades affecting countries across the economic spectrum.1 Type 2 diabetes is a leading risk factor for cardiovascular disease, which remains the number one cause of mortality worldwide.2
GLP-1 receptor agonists improved clinical outcomes related to kidney and heart health while lowering mortality rates for individuals with diabetes, chronic kidney disease or preexisting…
Missed diagnosis of PCOS was associated with Black vs White race, Medicaid vs private insurance, and normal BMI vs overweight BMI.
The COVID-19 pandemic reminded us of what vaccines can do to prevent life-threatening diseases.1 Respiratory infections such as influenza, COVID-19, respiratory syncytial virus (RSV), and…
Coadministered mRNA-1345 plus SIIV4 or mRNA-1273.214 vaccines had acceptable safety profiles and elicited mostly non-inferior immune responses compared to individual vaccines in adults aged 50…
New policy brief from World Obesity, analysing the global disparities in paediatric weight management.
Collaborate and connect with peers on clinical care and research related to bone and mineral metabolism/disorders. Date: Tuesday, March 26, 2024 Time: 11:30 AM –…
Phaeochromocytomas and paragangliomas (PPGLs) release catecholamines leading to catecholamine-induced hypertensive (CIH) crises, with blood pressure greater than or equal to 180/120 mm Hg. CIH crises…
Adults with heterozygous familial hypercholesterolaemia in most WHO regions have a higher type 2 diabetes prevalence than in Europe. Obesity markedly increases the risk of…
In most countries, especially in low-income and middle-income countries, diabetes treatment has not increased at all or has not increased sufficiently in comparison with the…
Addressing obesity must be at the heart of the global NCD response if we are to stem the tide of rising NCDs.
